These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Randomized, comparative study to evaluate efficacy and safety of doxazosin versus nitrendipine in the treatment of mild to moderate hypertension].
    Author: Sanz Guajardo D, Espejo Martínez J.
    Journal: An Med Interna; 1997 Jan; 14(1):15-9. PubMed ID: 9091027.
    Abstract:
    Doxazosin, an alfa-1 adrenoceptor antagonist, was compared with nitrendipine, a calcium antagonist, to evaluate their efficacy and safety in 61 patients with mild to moderate hypertension. 31 patients were assigned randomly to receive 1-16 mg of doxazosin and 30 patients were assigned to 10-20 mg of nitrendipine during 14 weeks (10 weeks of titration and 4 weeks of maintenance). Mean final dose was 6.1 mg for doxazosin and 15.6 mg for nitrendipine. Both treatments reduced supine and standing diastolic and systolic blood pressure (p < 0.01 for all comparisons). 22 patients in the doxazosin group (78.6%) and 18 in the nitrendipine group (78.3%) were considered therapy successes. There were not clinically significant changes in laboratory tests for both groups. Global assessment of adverse events was similar for both treatments (46.7% for doxazosin and 44.8% for nitrendipine), although patients treated with nitrendipine presented facial rush (20%) against none of the doxazosin group (p < 0.05). Withdrawals due to adverse events were higher in the nitrendipine group than in the doxazosin one (20.7% versus 6.7%, p = 0.14). The results of this study confirms that both antihypertensives reduced blood pressure in patients with mild to moderate hypertension. Furthermore, doxazosin treatment demonstrates a fewer number of withdrawals caused by adverse events.
    [Abstract] [Full Text] [Related] [New Search]